tbuckley/cabot-search huggingface dataset:
Abstract 17370: Pulmonary Vasodilation by Argon Ventilation in Rat Isolated Lungs is Nitric Oxide-Dependent
Authors: Hunter F Douglas, Claudius Balzer, Michele M Salzman, Jason A Bartos, Demetris Yannopoulos, Tom P Aufderheide, Matthias L Riess
Journal: Circulation (2017)

Introduction: Ventilation with the noble gas Argon during cardiopulmonary resuscitation (CPR) improved hemodynamics and demonstrated an antiarrhythmic effect in a porcine model of cardiac arrest. Hypothesis: Ventilation with Argon has a Nitric Oxide (NO)-dependent vasodilatory effect on the pulmonary vasculature allowing more right-to-left-flow during CPR. Methods: We isolated lungs from 8-week old Brown Norway rats and positive-pressure ventilated them with 10 mL/kg body weight. Both the pulmonary artery (PA) and the left atrium were cannulated for in- and outflow, respectively, and lungs were perfused at constant flow of 40 mL/kg body weight with a 4% Albumin Physiological Saline solution. During 30 min stabilization and for an additional 60 min of measurements, the lungs were ventilated with a 30% O2, 65% N2, 5% CO2 gas mixture. Ventilation was then switched for 60 min to 30% O2, 65% Argon, 5% CO2, followed by 20 min with 30% O2, 65% N2, 5% CO2. This was repeated in the presence of 100 μM of the non-sp...
Binimetinib plus Gemcitabine and Cisplatin Phase I/II Trial in Patients with Advanced Biliary Cancers
Authors: Maeve A. Lowery, Mikaela Bradley, Joanne F. Chou, Marinela Capanu, Scott Gerst, James J. Harding, Imane El Dika, Michael Berger, Ahmet Zehir, Ryan Ptashkin, Philip Wong, Teresa Rasalan-Ho, Kenneth H. Yu, Andrea Cercek, Ezra Morgono, Erica Salehi, Emily Valentino, Ellen Hollywood, Eileen M. O'Reilly, Ghassan K. Abou-Alfa
Journal: Clinical Cancer Research (2018)

Mutations in the RAS/RAF/MEK/ERK signaling pathway are commonly found in biliary tract cancer (BTC). Binimetinib, a selective inhibitor of MEK1/2, has single-agent activity. Preclinical data support binimetinib combination with chemotherapy, when given in an interrupted dosing schedule.Patients and Methods: A phase I/II trial evaluated binimetinib in combination with gemcitabine and cisplatin in patients with untreated advanced BTC. The primary endpoints were to determine the MTD (phase I), and PFS 6 and RR (phase II). Tumor tissue for targeted gene sequencing and blood samples for peripheral blood pERK expression were evaluated. Patients received oral binimetinib twice daily with gemcitabine and cisplatin on day 8 and 15 of a 21-day cycle. Binimetinib was held for 2 days prior to and on day of each chemotherapy treatment.Twelve patients enrolled in the phase I showed the MTD of binimetinib at 45 mg orally twice daily with gemcitabine 800 and cisplatin 20 mg/m2. Twenty-nine patients were treated in the phase II. Six patients treated at MTD in phase I were evaluable as part of phase II. PFS 6 months was 54% and RR was 36%. Median overall survival was 13.3 months (95% CI, 9.8-16.5). MSK-IMPACT 410-gene panel showed aberrations in the RAS-RAF-MEK-ERK pathway and mutations in PIK3CA, AKT2, PIK3CG, BRAF, and MAP3K1 in responding patients.Binimetinib with gemcitabine and cisplatin did not show an improvement in PFS 6 and RR. Molecular profiling may help select patients who may benefit from this triplet therapy, which is not planned at this time.
Oral Vitamin C (500 mg/d) to Pregnant Smokers Improves Infant Airway Function at 3 Months (VCSIP). A Randomized Trial
Authors: Cindy T. McEvoy, Lyndsey E. Shorey-Kendrick, Kristin Milner, Diane Schilling, Christina Tiller, Brittany Vuylsteke, Ashley Scherman, Keith Jackson, David M. Haas, Julia Harris, Robert Schuff, Byung S. Park, Annette Vu, Dale F. Kraemer, Julie Mitchell, Jill Metz, David Gonzales, Carol Bunten, Eliot R. Spindel, Robert S. Tepper, Cynthia D. Morris
Journal: American Journal of Respiratory and Critical Care Medicine (2018)

We reported a randomized trial demonstrating daily supplemental vitamin C to pregnant smokers significantly improved newborn pulmonary function tests. The current study tests these results in a new cohort using infant pulmonary function tests.
Feasibility of Treatment Discontinuation in Chronic Myeloid Leukemia in Clinical Practice in Spain: Results from a Nationwide Series of 236 Patients
Authors: Juan Carlos Hernandez Boluda, Arturo Pereira, Irene Pastor-Galán, Alberto Alvarez-Larrán, Alisa Savchuk, Jose Manuel Puerta, Jose M. Sanchez, Rosa Collado, Álvaro Díaz, Anna Angona, Miguel Sagüés, Valentín García Gutiérrez, Concepcion Boque, Ignacio Gómez-Centurión, Rolando Vallansot, Luis Palomera, Arantxa Mendizábal, Luis Felipe Casado, Manuel Pérez-Encinas, Raul Perez Lopez, Francisca Ferrer Marin, Fermin Sanchez-Guijo, Carmen Garcia-Hernandez, Natalia de las Heras, Jose Luiz Lopez Lorenzo, Francisco Cervantes, Juan Luis Steegmann
Journal: Blood (2018)
OP-106 Horizon — Melflufen Therapy for RRMM Patients Refractory to Daratumumab and/or Pomalidomide; Updated Results and First Report on PFS
Authors: Paul Richardson, Enrique Ocio, Albert Oriol, Alessandra Larocca, Paula Rodriguez Otero, Jan Moreb, Joan Bladé, Hani Hassoun, Michele Cavo, Adrián Alegre, Amitabha Mazumder, Christopher Maisel, Agne Paner, Nashat Gabrail, Jeffrey A Zonder, Dharminder Chauhan, Johan Harmenberg, Sara Thuresson, Hanan Zubair, Maria-Victoria Mateos
Journal: Blood (2018)
Human Breast Cancer Xenograft Model Implicates Peroxisome Proliferator–activated Receptor Signaling as Driver of Cancer-induced Muscle Fatigue
Authors: Hannah E. Wilson, Kacey K. Rhodes, Daniel Rodriguez, Ikttesh Chahal, David A. Stanton, Joseph Bohlen, Mary Davis, Aniello M. Infante, Hannah Hazard-Jenkins, David J. Klinke, Elena N. Pugacheva, Emidio E. Pistilli
Journal: Clinical Cancer Research (2018)

Abstract Purpose: This study tested the hypothesis that a patient-derived orthotopic xenograft (PDOX) model would recapitulate the common clinical phenomenon of breast cancer–induced skeletal muscle (SkM) fatigue in the absence of muscle wasting. This study additionally sought to identify drivers of this condition to facilitate the development of therapeutic agents for patients with breast cancer experiencing muscle fatigue. Experimental Design: Eight female BC-PDOX–bearing mice were produced via transplantation of tumor tissue from 8 female patients with breast cancer. Individual hind limb muscles from BC-PDOX mice were isolated at euthanasia for RNA-sequencing, gene and protein analyses, and an ex vivo muscle contraction protocol to quantify tumor-induced aberrations in SkM function. Differentially expressed genes (DEG) in the BC-PDOX mice relative to control mice were identified using DESeq2, and multiple bioinformatics platforms were employed to contextualize the DEGs. Results: We found that SkM from BC-PDOX–bearing mice showed greater fatigability than control mice, despite no differences in absolute muscle mass. PPAR, mTOR, IL6, IL1, and several other signaling pathways were implicated in the transcriptional changes observed in the BC-PDOX SkM. Moreover, 3 independent in silico analyses identified PPAR signaling as highly dysregulated in the SkM of both BC-PDOX–bearing mice and human patients with early-stage nonmetastatic breast cancer. Conclusions: Collectively, these data demonstrate that the BC-PDOX model recapitulates the expected breast cancer–induced SkM fatigue and further identify aberrant PPAR signaling as an integral factor in the pathology of this condition.
Updated Results of a Phase 2 Study of Modified Lenalidomide, Bortezomib, and Dexamethasone (RVd-lite) in Transplant-Ineligible Multiple Myeloma
Authors: Elizabeth K. O'Donnell, Jacob P. Laubach, Andrew J. Yee, Robert Redd, Carol Ann Huff, Frank Basile, Philip M. Wade, Claudia E. Paba-Prada, Irene M. Ghobrial, Robert L. Schlossman, Jill N. Burke, Cynthia C. Harrington, Kathleen J. Lively, Hannah Lyons, Nikhil C. Munshi, Kenneth C. Anderson, Paul G. Richardson, Noopur S. Raje
Journal: Blood (2019)
Targeting Bcl-2 and CD38 As Part of Personalized HSCT Conditioning Regimen in Chemorefractory Pediatric Leukemia
Authors: Maria Alyabeva, Larisa Shelikhova, Larisa Shelikhova, Daria Shasheleva, Rimma Khismatullina, Svetlana Radygina, Anna Bogoyavlenskaya, Sergey Blagov, Olga Molostova, Svetlana Kozlovskaya, Irina Kalinina, Elena Kurnikova, Yakov Muzalevsky, Dmitriy Pershin, Alexander Popov, Olga Illarionova, Yulia Olshanskaya, Natalia Miakova, Dmitry Litvinov, Galina Novichkova, Alexey A. Maschan, Michael Maschan
Journal: Blood (2018)